Erenumab (CALCRL, CGRP-R)

Size

£749.00

SKU:: 591841
Purity:: ≥95%
Storage Conditions:: -20°C
Supplier:: United States Biological
Host:: Human
Immunogen:: Recombinant protein corresponding to CALCRL/CGRP-R [Homo sapiens], expressed in CHO cells.
Format:: Supplied as a liquid in PBS, pH 7.5.
Extra Details:: Erenumab (AMG-334) (INN, trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine . Applications: Suitable for use in ELISA and SDS-PAGE. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.